ArticleAntimicrobial agents and chemotherapy2010
In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates.
Article in Antimicrobial agents and chemotherapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed.
- Optimizing antifungal dosing for invasiveFrontiers in pharmacology · 2025Article
- Genetic diversity and antifungal susceptibilities of environmental Cryptococcus neoformans and Cryptococcus gattii species complexes.IMA fungus · 2024Article
- Molecular epidemiological investigation ofMicrobiology spectrum · 2024Article
- Antifungal Resistance in Cryptococcal Infections.Pathogens (Basel, Switzerland) · 2024Review
- Genotyping Analysis ofJournal of fungi (Basel, Switzerland) · 2023Article
- Distribution and Polymorphisms of Group I Introns in Mitochondrial Genes fromJournal of fungi (Basel, Switzerland) · 2023Article
- Genotypic Diversity and Antifungal Susceptibility of Clinical Isolates of Cryptococcus Gattii Species Complex from Argentina.Mycopathologia · 2023Article
- Review
- A Fatal Fungal Infection:Open forum infectious diseases · 2022Article
- Molecular type distribution and fluconazole susceptibility of clinical Cryptococcus gattii isolates from South African laboratory-based surveillance, 2005-2013.PLoS neglected tropical diseases · 2022Article
- In Silico Structural Modeling and Analysis of Interactions ofInternational journal of molecular sciences · 2021Article
- Review
- Molecular Markers Reveal Epidemiological Patterns and Evolutionary Histories of the Human PathogenicFrontiers in cellular and infection microbiology · 2021Review
- Clinical and microbiological characteristics of Cryptococcus gattii isolated from 7 hospitals in China.BMC microbiology · 2020Article
- Cryptococcus genetic diversity and mixed infections in Ivorian HIV patients: A follow up study.PLoS neglected tropical diseases · 2019Article
- Antifungal potential of punicalagin against Cryptococcus neoformans species complex.Revista do Instituto de Medicina Tropical de Sao Paulo · 2018Article
- Case report: A fatal case of cryptococcosis in an immunocompetent patient due toJMM case reports · 2018Article
- Flucytosine resistance in Cryptococcus gattii is indirectly mediated by the FCY2-FCY1-FUR1 pathway.Medical mycology · 2018Article
- DifferentialInfection and immunity · 2018Article
- The status of cryptococcosis in Latin America.Memorias do Instituto Oswaldo Cruz · 2018Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The in vitro susceptibilities of a worldwide collection of 350 Cryptococcus gattii isolates to seven antifungal drugs, including the new triazole isavuconazole, were tested. With amplified fragment length polymorphism (AFLP) fingerprinting, human, veterinary, and environmental C. gattii isolates were subdivided into seven AFLP genotypes, including the interspecies hybrids AFLP8 and AFLP9. The majority of clinical isolates (n = 215) comprised genotypes AFLP4 (n = 76) and AFLP6 (n = 103). The clinical AFLP6 isolates had significantly higher geometric mean MICs for flucytosine and fluconazole than the clinical AFLP4 isolates. Of the seven antifungal compounds examined in this study, isavuconazole had the lowest MIC(90) (0.125 μg/ml) for all C. gattii isolates, followed by a 1 log(2) dilution step increase (MIC(90), 0.25 μg/ml) for itraconazole, voriconazole, and posaconazole. Amphotericin B had an acceptable MIC(90) of 0.5 μg/ml, but fluconazole and flucytosine had relatively high MIC(90)s of 8 μg/ml.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.